1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key Points:
Alcidion buys Telstra Health’s patient flow portfolio to add 33 ANZ customers and earnings Regulated data platform underpins cautious, efficiency-focused AI deployment in hospitals Strong UK growth with major contracts and relatively low market penetration supports guidance
Kate Quirke sets out how Alcidion’s acquisition of Telstra Health’s Kyra patient flow products, for $3 million, is intended to deepen its presence in hospital workflows. The deal is said to bring across 33 hospital and health system customers in Australia and New Zealand, adding more than $1 million of underlying EBITDA and expanding Alcidion’s installed base for its Miya Precision digital health platform. Quirke stresses the opportunity to migrate these sites onto Alcidion’s modern cloud environment and broaden usage beyond pure patient flow.
Quirke states that Alcidion’s regulated data platform is designed as a “system of record” that enables safe deployment of AI in a highly regulated healthcare setting. Existing AI-enabled modules are already cleared as software-as-a-medical-device, and current priorities are described as improving efficiency rather than replacing clinicians, for example by automating administrative tasks and record analysis.
On trading, Quirke points to continued contract momentum, cash-flow positivity and guidance for FY revenue above $50 million and EBITDA above $5 million, excluding the Telstra Health acquisition. UK contracts such as Northumbria and University Hospitals Sussex are highlighted, with the UK now accounting for about half of revenue and only around 15–18% market penetration. Quirke flags Canada and the Middle East as next expansion targets, with Canada potentially a springboard into the US, and suggests ongoing delivery and new geographies could re-rate the share price (ASX:ALC).
